Exscientia (NASDAQ:EXAI) Coverage Initiated by Analysts at TD Cowen

Equities researchers at TD Cowen initiated coverage on shares of Exscientia (NASDAQ:EXAIGet Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the stock.

Separately, Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Read Our Latest Analysis on Exscientia

Exscientia Stock Performance

Shares of EXAI stock opened at $5.73 on Tuesday. The firm has a 50-day moving average of $5.16 and a 200-day moving average of $5.61. The company has a market cap of $692.70 million, a P/E ratio of -4.37 and a beta of 0.84. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.30 and a quick ratio of 6.30. Exscientia has a one year low of $3.86 and a one year high of $9.12.

Exscientia (NASDAQ:EXAIGet Free Report) last announced its earnings results on Tuesday, May 21st. The company reported ($0.21) EPS for the quarter. The firm had revenue of $6.70 million during the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. Equities research analysts forecast that Exscientia will post -1.07 EPS for the current fiscal year.

Institutional Trading of Exscientia

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after buying an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after purchasing an additional 4,104 shares during the period. Walled Lake Planning & Wealth Management LLC bought a new position in Exscientia during the fourth quarter worth about $64,000. Colonial River Wealth Management LLC bought a new position in Exscientia during the fourth quarter worth about $86,000. Finally, New Republic Capital LLC bought a new position in shares of Exscientia in the fourth quarter valued at approximately $128,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

About Exscientia

(Get Free Report)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

Further Reading

Analyst Recommendations for Exscientia (NASDAQ:EXAI)

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.